February 16, 2022 10:43 AM ESTUpdated 01:46 PM
R&D

With de­layed re­view date loom­ing, Bris­tol My­ers un­corks more win­ning da­ta for block­buster-po­ten­tial heart drug

Kyle Blankenship

Bris­tol My­ers Squibb doled out a whop­ping $13 bil­lion for MyoKar­dia back in late 2020, main­ly on the block­buster hopes of heart drug mava­camten …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

Kathy High leads GV, ARCH-backed eye dis­ease biotech; Arv­inas com­mer­cial ex­ec steps down

A service from the Financial Times